RxDoctor Payments DataLook up a doctor →

Michele Henson, MD

Allergy & Immunology · Pooler, GANPI 1306993126

Payments from drug & device makers

$14,170in general payments, 2019–2025

Across 710 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • AstraZeneca$2K
  • Sanofi$1K
  • Biocryst US Sales Co., LLC$1K
  • CSL Behring$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $6K from 27 others

What the payments were for

  • Consulting fees$230%
  • Food & beverage$13,99199%
  • Education$1561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,170 in reported general payments places this provider in the 75th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$244,061
Medicare patients
388
Services billed
15,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$34,306
Qvar RedihalerBeclomethasone Dipropionate20$7,399
Ipratropium Bromide157$7,073
SymbicortBudesonide/Formoterol Fumarate26$6,581
Azelastine-FluticasoneAzelastine/Fluticasone21$4,644
Epinephrine20$3,883
Levocetirizine Dihydrochloride165$2,305
Desloratadine58$2,296
Montelukast Sodium129$2,044
Azelastine Hcl47$1,857
Mometasone Furoate11$1,203
Albuterol Sulfate HfaAlbuterol Sulfate34$1,041
Fluticasone Propionate54$887
Flunisolide13$505
Famotidine20$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$821$34,30639 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$56$7,39920 claims
AstraZenecaSymbicort$1,637$6,58126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Pooler

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →